Redeye maintains its valuation of Medicover after today's Q2 report. Medicover has proven resilient, the crisis has been temporary and management has navigated well through the many challenges. While we maintain our base case of SEK 127 per share, we raise our bull case to SEK 150. We see the current price levels as a good opportunity for investors looking for steady and resilient growth to build up a position.